0D53.LSE Financiere de Tubize SA
- Market cap
- EUR 9.08B
- P/E
- 26.8x
- P/B
- -
- ROE
- 9.5%
- Dividend yield
- 0.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Jun 2019.
Is 0D53.LSE undervalued?
Graham numberThe Graham number of Financiere de Tubize SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Financiere de Tubize SA fundamental analysis
No fundamental analysis for Financiere de Tubize SA yet.
Financiere de Tubize SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Financiere de Tubize SA
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.
Full company profileFinanciere de Tubize SA financial statements
2019 annualized: Fiscal year 2019 is not finished. Income statement and cash flow are annualized from 4 quarters up to Jun 30, 2019, the balance sheet is the latest quarter. Figures change when the annual report is published.
Financiere de Tubize SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 Anlz |
|---|---|
| Income Statement | |
| Operating Income | -894K |
| Net Income | 235M |
| Balance Sheet | |
| Total Assets | 2.55B |
| Total Liabilities | 87.2M |
| Shareholders' Equity | 2.46B |
| Cash & Short-term Investments | 1.02M |
| Cash Flow | |
| Operating Cash Flow | -1.11M |
| Capital Expenditure | 0.00 |
| Ratios | |
| ROE | 9.5% |
| ROA | 9.2% |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Financiere de Tubize SA dividends
Financiere de Tubize SA has not paid dividends in the last 1 fiscal years.
Who owns Financiere de Tubize SA
- Insiders 53.49%
- Institutions 9.01%
- Public & others 37.50%
- Shares outstanding 44.5M
- Free float 20.7M
Financiere de Tubize SA company profile
- Company name
- Financiere de Tubize SA
- Ticker
- 0D53.LSE
- ISIN
- BE0003823409
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- Allée de la Recherche 60, Brussels, Belgium, 1070
- Phone
- 32 4 9751 5208
- Website
- financiere-tubize.be
About Financiere de Tubize SA
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.
Financiere de Tubize SA management
2- Mr. Eric NysManaging Director
- Ms. Anne Sophie PijckeGeneral Manager